Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
Q1 2022 vs. Q4 2021
How the institutions holding Ambrx Biopharma, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 16 | 14 | −2 |
| Shares | 16.8M | 17.1M | +306.3K (+1.8%) |
| Value | $152.0M | $70.6M | −$81.4M (−53.5%) |
New holders (0)
Institutions that held Ambrx Biopharma, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
None.
Sold out (2)
Institutions that held Ambrx Biopharma, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Caas Capital Management LP | 13,068 | $118.0K |
| Migdal Insurance & Financial Holdings Ltd. | 124 | $1.00K |